Clinical trial NCT00914316: Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities
Official title: Supervised Treadmill Exercise and Ranolazine for Intermittent Claudication of Lower Extremities. THE STERILE TRIAL.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Peripheral Arterial Disease
Keywords: Lower leg claudication
Poor circulation of the leg muscles
Cramping or discomfort in the lower legs
Lower leg pain
PAD (Peripheral arterial disease)
Lead sponsor: William Beaumont Hospitals
Sponsor class: OTHER
First posted: 2009-06-04
Enrollment: 29
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The goal of this study is to evaluate whether supervised treadmill exercise combined with ranolazine 1000 mg twice daily provides an incremental benefit in absolute walking distance over supervised exercise alone in patients with stable claudication. Investigators also seek to determine if the administration of ranolazine provides a sustained benefit after the completion of a supervised exercise regimen. Lastly, investigators wish to determine whether both exercise and ranolazine improves peak oxygen consumption and anaerobic threshold in patients with stable claudication.

Detailed description: The treatment groups are:

A. Group A will be randomized to a 12 week supervised exercise program and ranolazine, (Ranexa) 1000 mg orally, twice daily, by mouth.

B. Group B will be randomized to a 12 week supervised exercise program and placebo.

After the 12 week supervised exercise program, all participants will undergo a second randomization to ranolazine or placebo for an additional 12 weeks, during which independent walking will be encouraged.

Both groups will participate in a two week lead-in period after each randomization of the trial, allowing for the stabilization of their medications and dosing of ranolazine. Medications such as cilostazol, calcium channel blockers and nitrates will be discontinued during the lead-in period, unless their use is for management for high blood pressure. Anti-platelet (blood thinner) medications will be continued throughout the trial.

Eligibility criteria: Inclusion Criteria:

* Males or females greater than 40 years of age.
* Documented peripheral arterial disease
* Stable lower extremity intermittent claudication (Rutherford class 1-3) for 3 months.

Exclusion Criteria:

* Critical limb ischemia (Rutherford class 4-6).
* Percutaneous or surgical lower extremity revascularization within last 12 months.
* Myocardial infarction within the last 6 months.
* cardiac surgery within the last 6 months.
* Unstable angina
* Stable chronic angina
* New York Heart Association Class II-IV heart failure
* Left ventricular ejection fraction less than or equal to 35%
* Venous thromboembolism within the last 6 months.
* Uncontrolled high blood pressure, defined as systolic blood pressure greater than or equal to 180 mmHg or diastolic blood pressure greater than or equal to 110 mmHg.
* Allergy to ranolazine.
* corrected QT interval (QTc) greater than or equal to 440 ms in males or 460 ms in females.
* Pregnant or nursing females.
* Chronic dialysis therapy.
* Significant liver impairment (defined as transaminases greater than or equal to 3 times the upper limit of normal) within the last 6 months.
* Concomitant use of Cytochrome P450-3A (CYP3A) inhibitors
* Concomitant use of CYP3A inducers
* QTc prolonging agents
* Orthopedic or neurologic disorders that prevent treadmill walking.
* Current participation in a structured exercise program.

Primary outcomes:
measure: Percentage Increase in Absolute Walking Distance Following Phase 1
timeFrame: 12 weeks
Secondary outcomes:
measure: Percentage Increase in Absolute Walking Distance Following Phase 2
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Royal Oak
country: United States
facility: William Beaumont Hospital
state: Michigan
Study officials:
affiliation: William Beaumont Hospitals
name: Laura Franny, M.D.
role: PRINCIPAL_INVESTIGATOR
References: